Literature DB >> 21209595

Radiation-induced sarcoma in a large vestibular schwannoma following stereotactic radiosurgery: case report.

William R Schmitt1, Matthew L Carlson, Caterina Giannini, Colin L W Driscoll, Michael J Link.   

Abstract

BACKGROUND AND IMPORTANCE: Stereotactic radiosurgery (SRS) has been employed with increasing frequency in the treatment of benign intracranial tumors. While the risk for radiation-induced malignancy has been well studied for fractionated external beam radiation, reports of SRS-associated malignancy have only begun to emerge over the past 10 years. CLINICAL
PRESENTATION: We present a case of a rapidly enlarging, presumed sporadic vestibular schwannoma in a 51-year-old man treated with SRS. Serial imaging over the next 7.5 years demonstrated good radiographic response with consistent involution of the tumor. The patient then developed rapid neurologic deterioration and sustained tumor growth on follow-up imaging. The tumor was resected via a translabyrinthine approach, and pathologic analysis demonstrated undifferentiated high-grade pleomorphic sarcoma (UHGPS).
CONCLUSION: This is the first report of undifferentiated high-grade pleomorphic sarcoma (formerly called malignant fibrous histiocytoma) following SRS. This case demonstrates the difficulty of establishing malignant degeneration of a neoplasm following SRS without pretreatment tissue diagnosis. Patients with presumed benign tumors should be counseled about the rare risk of malignant transformation prior to undertaking SRS. Copyright (C) by the Congress of Neurological Surgeons

Entities:  

Mesh:

Year:  2011        PMID: 21209595     DOI: 10.1227/NEU.0b013e31820780b1

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  8 in total

1.  Proposal for Modification of Cahan's Criteria Utilizing Molecular Genetic Analyses for Cases without Baseline Histopathology: A Unique Method Applicable to Primary Radiosurgery.

Authors:  Aaron E Rusheen; James B Smadbeck; Lisa A Schimmenti; Eric W Klee; Michael J Link; George Vasmatzis; Matthew L Carlson
Journal:  J Neurol Surg B Skull Base       Date:  2018-05-31

2.  Surgical management of vestibular schwannomas after failed radiation treatment.

Authors:  Yoichi Nonaka; Takanori Fukushima; Kentaro Watanabe; Allan H Friedman; Calhoun D Cunningham; Ali R Zomorodi
Journal:  Neurosurg Rev       Date:  2016-01-19       Impact factor: 3.042

Review 3.  Transition of a vestibular schwannoma to a malignant peripheral nerve sheath tumor with loss of H3K27 trimethylation after radiosurgery-a case report and review of the literature.

Authors:  Felix Behling; Imane Bersali; Antonio Santacroce; Johann Hempel; Kosmas Kandilaris; Jens Schittenhelm; Marcos Tatagiba
Journal:  Neurosurg Rev       Date:  2021-08-15       Impact factor: 2.800

4.  Stereotactic Radiosurgery versus Natural History in Patients with Growing Vestibular Schwannomas.

Authors:  Albert Tu; Peter Gooderham; Paul Mick; Brian Westerberg; Brian Toyota; Ryojo Akagami
Journal:  J Neurol Surg B Skull Base       Date:  2015-03-02

5.  What intervention is best practice for vestibular schwannomas? A systematic review of controlled studies.

Authors:  John G Wolbers; Alof Hg Dallenga; Alejandra Mendez Romero; Anne van Linge
Journal:  BMJ Open       Date:  2013-02-22       Impact factor: 2.692

6.  Intracranial Undifferentiated Sarcoma Arising from a Low-Grade Glioma: A Case Report and Literature Review.

Authors:  Bum-Joon Kim; Jong-Hyun Kim; Hung-Seob Chung; Taek-Hyun Kwon
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

7.  A case of infected schwannoma mimicking malignant tumor.

Authors:  Mamer S Rosario; Norio Yamamoto; Katsuhiro Hayashi; Akihiko Takeuchi; Shinji Miwa; Hiroyuki Inatani; Takashi Higuchi; Hiroyuki Tsuchiya
Journal:  World J Surg Oncol       Date:  2016-12-07       Impact factor: 2.754

8.  Malignant Transformation in Vestibular Schwannoma: Clinical Study With Survival Analysis.

Authors:  Jiuhong Li; Qiguang Wang; Menglan Zhang; Guisheng Zhang; Si Zhang; Xuhui Hui
Journal:  Front Oncol       Date:  2021-04-14       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.